Background HER family receptors play a key role in tumor progression in several malignancies, such as colorectal, lung or breast cancer. The aims of this study were to investigate expression of HER-1, HER-2 and HER-3 in pancreatic cancer (PC) samples and evaluate the association between HER-family receptor expression and patients’ clinical outcomes. Methods Tissue samples from 91 PC patients were subjected to immunohistochemical staining to assess the expression of HER-1, HER-2 and HER-3. Semiquantitative scores of zero (no staining or staining in less than 10% of cancer cells), 1+, 2+ or 3+ were assigned to each sample based on the intensity of staining for HER receptors. Scores of 2+ or 3+ were defined as positive staining. Results HER-1 overexpression was observed in 41 out of 91 samples (45.1%), while HER-2 was not overexpressed in any of the analyzed samples. HER-3 was overexpressed in 37 samples (40.7%) and was found to be associated with advanced TNM stage. In particular, HER-3 was overexpressed in 12 out of 16 stage IV patients (75%) compared with only 33.3% of stage I-III patients (p = 0.02). Among 79 patients with available survival data, the 6 patients with strong HER-3 expression (score 3+) had a shorter survival compared with remaining patients (median overall survival 6.9 months vs. 12.3 months, respectively). Conclusions HER-1 and HER-3 were found to be expressed in a significant proportion of PC patients. Strong HER-3 expression represents an indicator of poor prognosis in PC patients, being associated with advanced stage and shorter survival.
HER family receptor expression and prognosis in pancreatic cancer / A. Bittoni, A. Mandolesi, K. Andrikou, M. Santoni, S. Alfonsi, A. Lanese, C. Loretelli, C. Pellei, F. Piva, M. Scarpelli, S. Cascinu. - In: THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS. - ISSN 0393-6155. - 30:3(2015 Jul 01), pp. e327-e332.
|Titolo:||HER family receptor expression and prognosis in pancreatic cancer|
|Parole Chiave:||EGFR; HER-2; HER-3; Pancreatic adenocarcinoma; Prognosis; Adenocarcinoma; Aged; Aged, 80 and over; Dimerization; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Single-Blind Method; Clinical Biochemistry; Cancer Research; Oncology; 2734; Medicine (all)|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Settore BIO/13 - Biologia Applicata
Settore MED/04 - Patologia Generale
Settore MED/03 - Genetica Medica
|Data di pubblicazione:||1-lug-2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.5301/jbm.5000157|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|HER family receptor expression and prognosis in pancreatic cancer.pdf||Publisher's version/PDF||Administrator Richiedi una copia|